Q1 Earnings Forecast for ETON Issued By B. Riley

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Investment analysts at B. Riley issued their Q1 2025 earnings estimates for Eton Pharmaceuticals in a research report issued to clients and investors on Thursday, January 9th. B. Riley analyst M. El-Saadi forecasts that the company will earn $0.03 per share for the quarter. B. Riley has a “Strong-Buy” rating on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.17) per share. B. Riley also issued estimates for Eton Pharmaceuticals’ Q4 2025 earnings at $0.12 EPS.

A number of other equities analysts have also recently issued reports on the company. Craig Hallum increased their target price on Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. HC Wainwright raised their price objective on shares of Eton Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, January 6th.

Eton Pharmaceuticals Price Performance

ETON stock opened at $13.42 on Monday. The company’s 50-day moving average is $11.85 and its 200-day moving average is $7.55. The stock has a market capitalization of $349.60 million, a PE ratio of -61.00 and a beta of 1.38. Eton Pharmaceuticals has a 1 year low of $3.03 and a 1 year high of $15.00.

Institutional Trading of Eton Pharmaceuticals

Several institutional investors have recently made changes to their positions in the company. Parkman Healthcare Partners LLC increased its stake in Eton Pharmaceuticals by 2.8% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company’s stock valued at $1,561,000 after buying an additional 7,029 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in Eton Pharmaceuticals in the third quarter worth $54,000. Jane Street Group LLC bought a new position in Eton Pharmaceuticals in the 3rd quarter valued at $90,000. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Eton Pharmaceuticals by 86.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock valued at $390,000 after purchasing an additional 30,167 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Eton Pharmaceuticals by 13.5% during the 3rd quarter. Geode Capital Management LLC now owns 272,696 shares of the company’s stock worth $1,637,000 after purchasing an additional 32,365 shares during the period. Institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.